- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386200
Web-based Approach in Nutrition and Diabetes
May 13, 2020 updated by: Ester Vitacolonna, Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Educational Approach, Clinical Nutrition and Type 2 Diabetes: Traditional Strategies and Innovative Technologies
The study aims to test web-based strategies, in overweight or obese participants at risk or affected by Type 2 Diabetes Mellitus , to promote adherence over time to a healthy lifestyle and nutritional medical therapy (TMN).
The study population includes 40 subjects, randomly allocated to web group (therapeutic reinforcement through web-based strategies) or traditional group (traditional educational approach).
Anthropometric and clinical parameters will be collected, as well as scores of validated questionnaires will be administered up to 12 months from the enrollment.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chieti, Italy, 66100
- Hospital "SS Annunziata"
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Overweight or obesity (BMI ≥25 kg/m2)
- Participants with or at risk of Type 2 Diabetes Mellitus
- Skills in the use web-based technologies and internet accessibility
Exclusion Criteria:
- Conditions that could interfere with the execution and completion of the project or failure adherence to the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WEB GROUP
Traditional approach integrated with web-based technologies.
|
Integration of "traditional" face-to-face educational approach with web-based technologies.
|
Other: TRADITIONAL GROUP
Traditional educational approach
|
"traditional" face-to-face educational approach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Body Weight
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of body weight (in kilograms) at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in BMI
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of BMI (kg/m^2) at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in body circumferences
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of body circumferences (in centimeters) at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in Systolic and Diastolic blood pressure
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of Systolic and Diastolic blood pressure (mm hg) at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in fasting blood glucose
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of fasting blood glucose (mg/dl) at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in HbA1C
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of HbA1C at baseline and after 3, 6, 9 and 12 months
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in Dietary habits estimated by PREvencion con DIetaMEDiterranea questionnaire (PREDIMED questionnaire)
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of Dietary habits at baseline and after 3, 6, 9 and 12 months.
Changes in dietary habits will be estimated using a 14-item PREDIMED questionnaire which is a questionnaire to assess the adherence to the Mediterranean diet, 0 being the minimum total score and 14 the maximum total score.
Higher values represent a higher adherence to the Mediterranean diet.
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in physical activity level estimated by the International Physical Activity Questionnaire (IPAQ) - short form
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of physical activity level at baseline and after 3, 6, 9 and 12 months.
Changes in the level of physical exercise will be estimated by the International Physical Activity Questionnaire (IPAQ-short form) which is a questionnaire to assess the level of physical activity.
Patients are asked to measure the average amount of time spent in sedentary behaviours and different intensity levels of physical activity.
The questionnaire obtains three different intensity levels of physical activity: low, moderate and high.
|
Baseline, month 3, month 6, month 9 and month12
|
Change from baseline in Quality of life by 36-item short form health survey (SF-36)
Time Frame: Baseline, month 3, month 6, month 9 and month12
|
Assessment of Quality of life by SF-36 at baseline and after 3, 6, 9 and 12 months.
The 36-Item Short Form Health Survey (SF-36) is a self-report generic quality of life measure.
The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) with scores ranging from 0 to 100.
Higher scores indicate greater self-reported quality of life.
|
Baseline, month 3, month 6, month 9 and month12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2019
Primary Completion (Anticipated)
October 1, 2020
Study Completion (Anticipated)
October 1, 2020
Study Registration Dates
First Submitted
May 5, 2020
First Submitted That Met QC Criteria
May 8, 2020
First Posted (Actual)
May 13, 2020
Study Record Updates
Last Update Posted (Actual)
May 15, 2020
Last Update Submitted That Met QC Criteria
May 13, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VITA02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on web-based thecnologies
-
Clínica BazterricaWithdrawn
-
University of SouthamptonCompletedType 2 Diabetes
-
Arizona State UniversityUniversity of Colorado, Denver; University of New MexicoUnknownChildhood Obesity | Childhood OverweightUnited States
-
NYU Langone HealthStanford University; Shaare Zedek Medical CenterCompletedAnxiety Disorders | Major Depression | Post Traumatic Stress DisorderIsrael
-
Seattle Children's HospitalCompletedChronic Pain | Headache | Central SensitisationUnited States
-
Henry Ford Health SystemNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Northwestern UniversityWithdrawnIndividuals at Risk for DepressionUnited States
-
University of North Carolina, Chapel HillRTI InternationalCompletedObesity | Overweight
-
Georgetown UniversityAlbert Einstein College of Medicine; University of MichiganCompletedTobacco Cessation | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Virus, Human Immunodeficiency | Tobacco-Use DisorderUnited States
-
Taipei Medical UniversityRecruitingInfertility | Heart Rate Variability | BiofeedbackTaiwan